FDA approved Besponsa (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
The agent is sponsored by Pfizer Inc.
As NCI employees and others at HHS were receiving notices of termination, national cancer organizations called on Congress “to restore stability to NIH.”
